Potentiated antibodies to tumor necrosis factor-alpha in the therapy of patients with rheumatoid arthritis.
We studied the efficiency and safety of a new homeopathic preparation Artrofoon containing affinely purified antibodies to tumor necrosis factor-alpha in the therapy of patients with rheumatoid arthritis. Artrofoon produced a positive antiinflammatory effect on the course of rheumatoid arthritis. This preparation reduced the severity of arthralgia (indexes of Li and Ritchie) and morning stiffness and decreased the erythrocyte sedimentation rate and contents of rheumatoid factor and C-reactive protein. One-month therapy improved the state of patients. Artrofoon was well tolerable. The preparation did not cause the ulcerogenic and nephrotoxic effects. Artrofoon holds much promise for combination therapy of patients with rheumatoid arthritis (including severe articular-and-visceral forms) and complications after treatment with nonsteroid antiinflammatory preparations.
Kozlovskaya
L V
LV
Department of Therapy and Occupational Diseases, I. M. Sechenov Moscow Medical Academy.
Mukhin
N A
NA
Rameev
V V
VV
Sarkisova
I A
IA
Epstein
O I
OI
D000328:Adult; D000368:Aged; D000906:Antibodies / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000906:Antibodies; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; C503436:Artrofoon; D014409:Tumor Necrosis Factor-alpha